European Commission approves Sobi’s Aspaveli for the treatment of C3G and primary IC-MPGN: Stockholm Monday, January 19, 2026, 10:00 Hrs [IST] Sobi, a global biopharma company u ...
Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 ...
Health on MSN
How rare is complement 3 glomerulopathy?
Medically reviewed by David Ozeri, MD Complement 3 glomerulopathy (C3G) is considered a very rare disease. With C3G, patients have issues with their immune system that cause kidney damage and symptoms ...
Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the first treatment for C3G and primary IC-MPGN ...
Zacks Investment Research on MSN
Apellis stock crashes 23% in a week: Here's what you should know
Shares of Apellis Pharmaceuticals APLS have crashed 22.6% in the past week. The massive stock price decline was observed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback